A multi-target synergistic hair loss prevention composition, and a preparation method and application thereof
By using a multi-target synergistic anti-hair loss and hair growth composition to regulate the hair follicle microenvironment, the problem of single-function products in existing products is solved, and significant effects of promoting hair growth and reversing hair follicle degeneration are achieved.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- SHANGHAI YAOJIAN BIO TECH
- Filing Date
- 2026-05-20
- Publication Date
- 2026-06-19
AI Technical Summary
Existing hair loss prevention products have only one target and cannot systematically regulate the hair follicle microenvironment. In particular, their effect on downregulating TGF-β1, a key factor in hair follicle degeneration, is limited, resulting in poor response or difficulty in maintaining the effect for some patients.
This product employs a multi-target synergistic anti-hair loss and hair growth composition, including co-delivery nanoliposomes of pyrrolidine diaminopyrimidine oxide and diaminopyrimidine oxide, caffeine, type 17 collagen peptide, ginsenosides, pea sprout extract, and co-delivery nanoliposomes of melatonin. By promoting angiogenesis, stabilizing stem cell niches, activating growth-promoting signals, inhibiting regression signals, and resisting oxidative stress, it forms a six-dimensional synergistic effect to regulate the hair follicle microenvironment.
It significantly promotes hair growth, increases the number of hair follicles and dermal thickness, effectively downregulates TGF-β1 expression, and reverses the miniaturization process of hair follicles. Its effects are comprehensive and significantly superior to existing single-target drugs.
Smart Images
Figure CN122229992A_ABST
Abstract
Description
Technical Field
[0001] This application relates to the fields of biomedicine and cosmetics, and more specifically, to a multi-target synergistic composition for preventing hair loss and promoting hair growth, its preparation method, and its application. Background Technology
[0002] Androgenetic alopecia is the most common type of hair loss, affecting 30-50% of men and about 30% of middle-aged women. It is characterized by gradually thinning hair diameter, shortening hair length, and decreased pigmentation, ultimately leading to miniaturization of hair follicles. The core pathological mechanisms of hair loss involve multiple factors, including imbalance of hair follicle stem cell niche, disordered signaling pathways, abnormal vascular microenvironment, damage to the extracellular matrix (ECM), metabolic disorders, and excessive inflammatory responses.
[0003] Hair follicle growth is cyclical, consisting of three phases: anagen (growth phase), catagen (transitional phase), and telogen (resting phase). This dynamic balance is maintained by the activation and quiescence of HFSCs (hyperfollicular cells), regulation of signaling pathways, and the stability of the microenvironment. The anagen phase is the most active period of hair follicle growth, during which stromal cells continuously proliferate and differentiate to form the hair shaft; the length of this phase determines hair length. During the catagen phase, hair follicle growth ceases, cell proliferation and differentiation capacity decreases, apoptosis increases, and the hair follicle rapidly degenerates. During the telogen phase, hair follicle biological activity is at its weakest, and the hair shaft falls out, but the expression of HFSC regulatory factors increases, preparing for the next anagen phase. In healthy individuals, the ratio of anagen to telogen phases is approximately 14-12:1, while this ratio is significantly reduced in patients with hair loss, such as those with androgenetic alopecia (AGA), where it drops to 5:1. This is because TGF-β1 is upregulated by DHT in androgenetic alopecia, causing hair follicles to enter the catagen phase prematurely, shortening the anagen phase. This imbalance in the hair follicle cycle is a core pathological feature of hair loss.
[0004] Currently, topical minoxidil primarily improves hair follicle blood supply by opening ATP-sensitive potassium channels and dilating blood vessels, but its target is relatively singular. Studies have shown that minoxidil has limited effectiveness in downregulating TGF-β1 protein expression and cannot effectively repair damaged ECM or systemically regulate multiple signaling pathways, resulting in poor response or difficulty in maintaining the effect in some patients.
[0005] Therefore, developing a product that can act on the hair follicle microenvironment from multiple dimensions is a technical problem that urgently needs to be solved in this field. Summary of the Invention
[0006] To address the limitations of anti-hair loss products that target only one specific area, cannot systematically regulate the hair follicle microenvironment, and have a limited effect on downregulating TGF-β1, a key factor in hair follicle degeneration, this application provides a multi-target synergistic anti-hair loss and hair growth composition, its preparation method, and its application.
[0007] In a first aspect, this application provides a multi-target synergistic composition for preventing hair loss and promoting hair growth, employing the following technical solution: A multi-target synergistic composition for preventing hair loss and promoting hair growth, comprising the following components in parts by weight: 4-8 parts of co-delivered nanoliposomes containing pyrrolidinyl diaminopyrimidine oxide and diaminopyrimidine oxide; 1-5 servings of caffeine; Type 17 collagen peptides, 0.01-0.1 parts; Ginsenosides 1-5 parts; Pea sprout extract 0.5-3 parts; 0.005-0.05 parts of melatonin were co-delivered via nanoliposomes; Biotin 0.05-0.5 parts; Adenosine 0.3-1.5 parts.
[0008] By adopting the above technical solution, the hair follicle microenvironment is regulated at multiple targets through a six-dimensional synergistic effect of promoting angiogenesis, stabilizing stem cell niches, activating growth-promoting signals, inhibiting regression signals, resisting oxidative stress, and nutritional enhancement.
[0009] In this composition, pyrrolidine diaminopyrimidine oxide and diaminopyrimidine oxide liposomes synergistically optimize the vascular microenvironment surrounding hair follicles, providing a material basis for the efficient proliferation of hair follicle stem cells and stromal cells. Type 17 collagen peptides precisely target damaged stem cell niches, enhancing the anchoring and self-renewal capabilities of hair follicle stem cells, fundamentally delaying hair follicle aging. Ginsenosides and pea sprout extracts synergistically promote the transition of hair follicles from the resting phase to the anagen phase by activating the Wnt / β-catenin positive pathway and relieving BMP negative inhibition, respectively. Simultaneously, melatonin liposomes exert potent antioxidant and anti-inflammatory effects, protecting hair follicle cells from oxidative damage. The synergistic effect of these components in a specific ratio enables this composition not only to effectively promote hair growth but also to exhibit an unexpected technical effect—significantly downregulating the expression of TGF-β1, a key factor in hair follicle degeneration, which is not found in existing single-target drugs (such as minoxidil). This effectively reverses the miniaturization process of hair follicles, achieving a fundamental intervention in hair loss.
[0010] Perform performance testing: 1. A testosterone-induced androgenetic alopecia model was successfully established using C57BL / 6 male mice. Results after 28 days of continuous treatment showed that the proposed composition significantly increased the length and weight of newly grown hair in C57BL / 6 male mice, indicating its effective promotion of hair growth.
[0011] 2. H&E staining results of skin tissue sections showed that the composition of this invention can significantly increase the number of hair follicles and the thickness of the dermis in mice.
[0012] 3. Immunofluorescence staining results showed that the composition of this invention can effectively upregulate the expression of VEGF, β-catenin, and KGF, while its effect on downregulating the expression of TGF-β1 is significantly better than that of minoxidil.
[0013] Optionally, the co-delivered nanoliposomes of pyrrolidinyl diaminopyrimidine oxide and diaminopyrimidine oxide are prepared by high-pressure homogenization technology, and their average particle size is 99-101 nm.
[0014] By adopting the above technical solution: Pyrrolidinyl diaminopyrimidine oxide and diaminopyrimidine oxide, as structural analogs of minoxidil, have the potential to promote angiogenesis, but their poor transdermal absorption efficiency leads to insufficient effect. In this application, after encapsulation with a carrier, the skin cumulative permeation and skin retention of pyrrolidinyl diaminopyrimidine oxide (Kopexil) are increased. Nanoliposomes can significantly improve the delivery efficiency and accumulation of active ingredients in human dermal papillary cells (HDPCs), which helps to improve the anti-hair loss and hair growth effect of the composition.
[0015] Optionally, the melatonin co-delivery nanoliposomes are prepared using high-pressure homogenization technology.
[0016] By adopting the above technical solution: Although melatonin has excellent antioxidant and anti-inflammatory activities, it is highly polar and difficult to penetrate into the target site / target cell of skin care, resulting in low bioavailability, poor stability, and easy inactivation under light and heat. In this invention, melatonin co-delivery nanoliposomes prepared by high-pressure homogenization technology are selected. After being delivered to the skin by a carrier, the retention and bioavailability of melatonin in the skin can be effectively improved, so that it can give full play to its antioxidant and anti-inflammatory effects and form a synergistic effect with other growth-promoting ingredients in the composition.
[0017] Optionally, the composition further comprises the following components in parts by weight: 1-5 parts of Platycladus orientalis leaf extract, 0.02-0.1 parts of glutathione, 0.02-0.1 parts of β-sitosterol, 69-77 parts of water, 15 parts of propylene glycol, and 0.5 parts of preservative.
[0018] By adopting the above technical solution, auxiliary ingredients with specific effects are further introduced to achieve a more comprehensive optimization of the hair follicle microenvironment. Among them, Platycladus orientalis leaf extract, a traditional Chinese medicine, is rich in flavonoids and has good anti-inflammatory effects and improves local microcirculation; glutathione, as an endogenous antioxidant, can effectively replenish the intracellular sulfhydryl pool and assist melatonin in resisting DHT-induced oxidative stress damage; β-sitosterol, a phytosterol with a molecular structure similar to androgens, may locally antagonize the binding of DHT to androgen receptors through a competitive mechanism. The addition of these three ingredients supplements and strengthens the composition's effects in three dimensions: anti-inflammatory, antioxidant, and androgen antagonism, making the composition's effect on androgenetic alopecia more rigorous and comprehensive, further improving the effectiveness and durability of its anti-hair loss and hair regrowth effects.
[0019] Optional components may include the following parts by weight: Six parts of co-delivered nanoliposomes containing pyrrolidine diaminopyrimidine oxide and diaminopyrimidine oxide; two parts of caffeine; 0.02 parts of type 17 collagen peptide; two parts of ginsenosides; one part of pea sprout extract; two parts of arborvitae leaf extract; 0.01 parts of co-delivered nanoliposomes containing melatonin; 0.1 parts of biotin; 0.75 parts of adenosine; 0.05 parts of glutathione; and 0.05 parts of β-sitosterol. Water 72.62 parts; propylene glycol 15 parts; preservative 0.5 parts.
[0020] By adopting the above technical solution, when the components in the composition are in the above specific weight ratio, the overall effect of preventing hair loss and promoting hair growth is optimal, especially in the key indicator of downregulating TGF-β1 protein expression, it achieves a significantly better effect than the positive control drug minoxidil.
[0021] Secondly, this application provides the use of the above-described multi-target synergistic anti-hair loss and hair growth composition in the preparation of products for preventing, alleviating or treating hair loss.
[0022] By adopting the above technical solution, the composition has a multi-target, highly synergistic mechanism for preventing and promoting hair loss. When applied to the preparation of products for preventing, alleviating, or treating hair loss, it has extremely high application value and market prospects.
[0023] Optionally, the hair loss is androgenetic alopecia.
[0024] By adopting the above technical solution, the composition has a multi-dimensional effect on the core pathological mechanisms of androgenetic alopecia (AGA) (vascular abnormalities, ECM damage, Wnt / BMP / TGF-β signaling disorders, oxidative stress, etc.).
[0025] Optionally, the product may be in the form of a serum, spray, gel, cream, or shampoo.
[0026] By adopting the above technical solution, the composition has good pharmaceutical flexibility and can be easily prepared into a variety of external dosage forms according to actual application scenarios and user preferences.
[0027] Thirdly, this application provides a method for preparing the above-mentioned multi-target synergistic anti-hair loss and hair growth composition, using the following technical solution: A method for preparing the above-described multi-target synergistic anti-hair loss and hair growth composition, characterized by comprising the following steps: S1. Add propylene glycol and preservative to water, stir and mix well, then add adenosine, stir and mix, cool to 55-65℃, then add caffeine, stir and mix to obtain mixture A; S2. Dissolve glutathione and type 17 collagen peptide in water separately to obtain glutathione solution and type 17 collagen peptide solution. Add the two solutions together with β-sitosterol into mixture A and stir to obtain mixture B. S3. After cooling the mixture B to 40-50℃, add the co-delivery nanoliposomes of pyrrolidinyl diaminopyrimidine oxide and diaminopyrimidine oxide, pea sprout extract, ginsenosides, arborvitae leaf extract, co-delivery nanoliposomes of melatonin, and biotin. Stir and mix, and then cool to below 38℃ to obtain the final product.
[0028] By adopting the above-mentioned technical solution, the preparation method of this application utilizes a three-stage precise temperature control and step-by-step feeding process based on the distinct physicochemical properties of each active ingredient (such as thermosensitivity, solubility, and sensitivity to shear force). Specifically, stage one ensures the complete dissolution and homogenization of poorly soluble components such as adenosine and caffeine within the optimal temperature window; stage two prevents the thermal degradation of antioxidants; and stage three protects the integrity of the nanoliposome structure and the biological activity of type 17 collagen peptides, avoiding particle size changes and protein denaturation caused by high temperature or high shear force. Through precise temperature gradient control and feeding sequence design, the batch stability and bioactivity of the composition are significantly improved. Furthermore, the entire process is simple to operate, highly controllable, and can be directly integrated into industrial production lines, greatly reducing the difficulty and cost of commercial production.
[0029] In summary, this application has the following beneficial effects: 1. This application constructs a multi-target synergistic network of "promoting angiogenesis, stabilizing stem cell niches, activating growth-promoting signals, inhibiting regression signals, resisting oxidative stress, and nutritional enhancement"; experimental data show that this composition can not only promote hair growth, but also significantly increase dermal thickness and hair follicle number, effectively reverse hair follicle miniaturization, and has comprehensive and significant effects. 2. In this application, by preparing minoxidil analogues (pyrrolidine diaminopyrimidine oxide, diaminopyrimidine oxide) and melatonin into specific co-delivery nanoliposomes, the transdermal absorption efficiency and skin retention are significantly improved, and the bioavailability of active ingredients at the target site is enhanced, providing a material basis for efficient hair loss prevention and hair growth. 3. This application limits the ratio of each substance to the optimal range, resulting in a strong downregulation effect on TGF-β1 protein expression. Its effect is significantly better than that of the existing topical product minoxidil, which helps to fundamentally delay the hair follicle regression process. Attached Figure Description
[0030] Figure 1 These are images showing the changes in skin color and hair growth in the hairless area on the back of male C57BL / 6 mice over 28 days during the performance testing of this application. Figure 2 This is a diagram showing the H&E staining results of the dorsal skin of mice in each group on day 28 after hair removal in the performance test of this application. Figure 3 This is a graph showing the VEGF immunofluorescence detection results during the performance testing of this application; Figure 4 This is a graph showing the immunofluorescence detection results of β-catenin in the performance testing of this application; Figure 5 This is a graph showing the KGF immunofluorescence detection results during the performance testing of this application; Figure 6 This is a graph showing the results of TGF-β1 immunofluorescence detection during the performance testing of this application. Detailed Implementation
[0031] The present application will be further described in detail below with reference to the embodiments. The sources of each component are as follows, and unless otherwise specified below, the components are from commercially available sources:
[0032] Examples 1-3, Comparative Examples 1-2
[0033] A multi-target synergistic composition for preventing hair loss and promoting hair growth, the components and their corresponding weights are shown in Table 1, and it is prepared by the following steps: S1. Add propylene glycol and preservative (p-hydroxyacetophenone) to water and add to a mixing device. Stir and heat to 80°C until completely dissolved. Then add adenosine and stir until completely dissolved. After cooling the system to 60°C, add caffeine and stir normally until completely dissolved to obtain mixture A. S2. Mix glutathione and type 17 collagen peptide with an appropriate amount of water to obtain glutathione solution and type 17 collagen peptide solution respectively; add glutathione solution, type 17 collagen peptide solution and β-sitosterol to mixture A, stir until completely dissolved to obtain mixture B; S3. After cooling the mixture B to 45°C, add the co-delivery nanoliposomes of pyrrolidine diaminopyrimidine oxide and diaminopyrimidine oxide, pea sprout extract, ginsenosides, arborvitae leaf extract, co-delivery nanoliposomes of melatonin, and biotin. Stir and mix as usual, and then cool to below 38°C to obtain the final product.
[0034] Table 1. Components and their weights (kg) in Examples 1-6 and Comparative Examples 1-2
[0035] It should be noted that the process conditions and component selections in the embodiments of this application can be selected within the following ranges. The above selections do not have a significant impact on the detection data of this application. This application only uses one of them as an example for brief introduction, but it does not affect the application of other selections in this application: In step S1, the preservative can be selected from p-phenoxyethanol, ethylhexylglycerin, glyceryl caprylate, parabens, p-hydroxyacetophenone, capryloyl hydroxamic acid, sorbitan caprylate, and lauroyl arginine ethyl ester hydrochloride, with the sole purpose of providing a preservative effect on the composition; the stirring and heating should be carried out in the range of 70-85℃, and the cooling temperature of the system should be carried out in the range of 55-65℃; In step S3, the cooling temperature of mixture B is selected between 40-50℃; In Table 1, except for water, propylene glycol and preservatives, the amounts of each component are the weight parts of the active ingredient. The remaining parts of the composition are water and conventional excipients required for formulation. Their types and amounts can be conventionally selected by those skilled in the art according to actual needs. This application only briefly introduces water, propylene glycol and preservatives as examples.
[0036] Comparative Example 3
[0037] A multi-target synergistic composition for preventing hair loss and promoting hair growth, differing from Example 2 in that a mixture of equal amounts of pyrrolidinyl diaminopyrimidine oxide and diaminopyrimidine oxide in a weight ratio of 1:2 is used instead of pyrrolidinyl diaminopyrimidine oxide liposomes. Among them, pyrrolidinyl diaminopyrimidine oxide, manufacturer model: DH-GTH195, Chongqing Donghuan Technology Development Co., Ltd.; diaminopyrimidine oxide, manufacturer model: DH-GTH126, Chongqing Donghuan Technology Development Co., Ltd.
[0038] Comparative Example 4
[0039] A multi-target synergistic composition for preventing hair loss and promoting hair growth, which differs from Example 2 in that it does not contain type 17 collagen peptides.
[0040] Comparative Example 5
[0041] A multi-target synergistic composition for preventing hair loss and promoting hair growth, which differs from Example 2 in that it does not contain pea sprout extract.
[0042] Comparative Example 6
[0043] A multi-target synergistic composition for preventing hair loss and promoting hair growth, which differs from Example 2 in that it does not contain melatonin co-delivery nanoliposomes.
[0044] Performance testing
[0045] 1. Comparison of the composition of Example 5 and minoxidil: Construction and administration methods of animal models of androgenetic alopecia: A testosterone-induced androgenetic alopecia model was established using C57BL / 6 male mice. After one week of adaptive culture, the hair on the back was shaved off with an electric shaver, and further hair removal was performed using depilatory cream. The mice were randomly divided into 4 groups (n=10 per group): normal group, model group, composition group of Example 5 of this application, and minoxidil group.
[0046] In the normal group, 200 μL of physiological saline was applied to the hair-removed area on the back of the mice every day; The model group, the Example 5 composition group, and the minoxidil group were treated daily with 200 μL of 0.05% testosterone (dissolved in 75% ethanol) applied to the hairless area on the back of each mouse to serve as a model of androgenetic alopecia. After 30 minutes, 300 μL of the Example 5 composition and minoxidil (3%) were evenly applied to the hairless area on the back of C57BL / 6 male mice, while the model group received an equal volume of blank serum. The test solutions of each group were continuously applied to the back skin of C57BL / 6 male mice for 28 days.
[0047] Blank serum formula: 83.6% deionized water, 15% propylene glycol, 0.9% 1,2-hexanediol, 0.1% ethylhexylglycerin, 0.1% sodium hyaluronate, and 0.3% p-hydroxyacetophenone.
[0048] New hair growth assay: 28 days after drug administration, 30 newly grown hairs were randomly plucked from three different locations on the bald area of each mouse's back, and their length was measured using calipers. The newly grown hairs were also collected from the bald area, weighed using an analytical balance, and their length and weight were recorded. After hair shaving, skin tissue was taken from the back of the bald area parallel to the spine, fixed in 4% paraformaldehyde, sectioned, stained with H&E, observed under an optical microscope, and photographed from representative areas. The dermal thickness and number of hair follicles in the skin samples were analyzed and recorded.
[0049] Data results are expressed as Mean ± SD. The comparison between groups was performed using a two-tailed t-test. P < 0.05 was considered statistically significant, and P < 0.01 was considered highly statistically significant.
[0050] Table 2-1 Performance Test Results
[0051] Table 2-2 Relative Fluorescence Intensity
[0052] See Figure 1 As shown in Table 2, by day 14 of the experiment, the normal group mice had already grown hair, while the back skin of the model group mice remained pink, indicating that the hair was still in the quiescent phase. This indicates that the androgenic alopecia model was successfully established. The back skin of the mice in the Example 5 composition and minoxidil groups had turned black or had some new hair growth, indicating that the composition acted on the hair follicles in the bald area, and the hair follicles had begun to enter the growth phase, both of which promoted hair regeneration. By day 28 of the experiment, the skin of the model group mice had begun to turn black and some hair had grown. The hair growth status on the backs of the mice in the Example 5 composition and minoxidil groups was the same as that of the normal group mice, and the hair in the bald area on the back had fully grown. By day 28 of the experiment, the length and weight of the new hair in the Example 5 composition and minoxidil groups were significantly better than those in the model group mice, with a highly significant difference (P < 0.01).
[0053] See Figure 2 According to Table 2, compared with the normal group, the number of hair follicles and the thickness of the dermis in the model group mice were significantly reduced, indicating that the model was successful. Compared with the model group, the dermis thickness and the number of hair follicles in mice treated with the composition of this invention and minoxidil were increased.
[0054] To further elucidate the mechanism of hair growth promotion, the expression of VEGF, β-catenin, KGF, and TGF-β1-related proteins in the skin was studied using immunohistochemical staining. (See [link to study].) Figure 3-6 As shown in Table 2-2, compared with the model group, the fluorescence intensity of VEGF, β-catenin, and KGF in mouse skin treated with the invented composition and minoxidil was significantly increased, while the fluorescence intensity of TGF-β1 was significantly decreased. This indicates that the composition can upregulate the expression of VEGF, β-catenin, and KGF-related proteins related to hair growth, and downregulate the protein expression of TGF-β1. Moreover, the composition of Example 5 showed a stronger effect in downregulating the protein expression of TGF-β1 compared with minoxidil.
[0055] This demonstrates that the composition of this application not only possesses growth-promoting capabilities comparable to existing topical medications like minoxidil, but also has additional advantages in inhibiting hair follicle degeneration and delaying the hair loss process.
[0056] 2. Immunofluorescence experiments were performed on all compositions of the examples and comparative examples according to the above method, and the relative fluorescence intensity of mouse TGF-β1 was recorded. The results are recorded in Table 3.
[0057] Table 3. Relative fluorescence intensity of TGF-β1 in the examples and comparative examples
[0058] Referring to Table 3, comparing Example 2 and Comparative Example 3, it can be seen that when a mixture of free pyrrolidinyl diaminopyrimidine oxide and diaminopyrimidine oxide is used instead of the nanoliposomes, the relative fluorescence intensity of TGF-β1 is significantly increased, indicating that the nanoliposome delivery system is crucial for exerting the downregulation effect of the active ingredient on TGF-β1. Comparing Example 2 and Comparative Example 4, it can be seen that the effect of downregulating TGF-β1 is significantly weakened after the absence of type 17 collagen peptide, which proves that type 17 collagen peptide has an irreplaceable role in stabilizing the ecological niche of stem cells and synergistically inhibiting hair follicle degeneration signals. Comparing Example 2 with Comparative Example 5, it can be seen that the effect was reduced when pea sprout extract was missing, which verifies the mechanism by which it participates in synergistic enhancement through the regulation of BMP and other pathways. Comparing Example 2 with Comparative Example 6, it can be seen that the effect was significantly weakened after the absence of melatonin liposomes, proving that the antioxidant and anti-inflammatory effects of melatonin make an important contribution to the overall efficacy.
[0059] This specific embodiment is merely an explanation of this application and is not intended to limit it. After reading this specification, those skilled in the art can make modifications to this embodiment without contributing any inventive step, but such modifications are protected by patent law as long as they fall within the scope of the claims of this application.
Claims
1. A multi-target synergistic composition for preventing hair loss and promoting hair growth, characterized in that, The components include the following parts by weight: 4-8 parts of co-delivered nanoliposomes containing pyrrolidinyl diaminopyrimidine oxide and diaminopyrimidine oxide; 1-5 servings of caffeine; Type 17 collagen peptides, 0.01-0.1 parts; Ginsenosides 1-5 parts; Pea sprout extract 0.5-3 parts; 0.005-0.05 parts of melatonin were co-delivered via nanoliposomes; Biotin 0.05-0.5 parts; Adenosine 0.3-1.5 parts.
2. The multi-target synergistic anti-hair loss and hair growth composition according to claim 1, characterized in that: The co-delivery nanoliposomes of pyrrolyl diaminopyrimidine oxide and diaminopyrimidine oxide were prepared by high-pressure homogenization technology, and their average particle size was 99-101 nm.
3. The multi-target synergistic anti-hair loss and hair growth composition according to claim 1, characterized in that: The melatonin co-delivery nanoliposomes were prepared using high-pressure homogenization technology.
4. The multi-target synergistic anti-hair loss and hair growth composition according to claim 1, characterized in that: The composition further comprises the following components in parts by weight: 1-5 parts of Platycladus orientalis leaf extract, 0.02-0.1 parts of glutathione, 0.02-0.1 parts of β-sitosterol, 69-77 parts of water, 15 parts of propylene glycol, and 0.5 parts of preservative.
5. The multi-target synergistic anti-hair loss and hair growth composition according to claim 4, characterized in that, The components include the following parts by weight: Six parts of co-delivered nanoliposomes of pyrrolidine diaminopyrimidine oxide and diaminopyrimidine oxide; two parts of caffeine; 0.02 parts of type 17 collagen peptide; two parts of ginsenosides; one part of pea sprout extract; two parts of arborvitae leaf extract; 0.01 parts of co-delivered nanoliposomes of melatonin; 0.1 parts of biotin; 0.75 parts of adenosine; and 0.05 parts of glutathione. 0.05 parts of β-sitosterol; 72.62 parts water; 15 parts propylene glycol; 0.5 parts preservative.
6. The use of a multi-target synergistic hair loss prevention and hair growth composition as described in any one of claims 1-5 in the preparation of products for the prevention, relief or treatment of hair loss.
7. The application according to claim 6, characterized in that, The hair loss described is androgenetic alopecia.
8. The application according to claim 6, characterized in that, The product is available in the form of serum, spray, gel, cream, or shampoo.
9. A method for preparing the multi-target synergistic anti-hair loss and hair growth composition according to claim 4 or 5, characterized in that, Includes the following steps: S1. Add propylene glycol and preservative to water, stir and mix well, then add adenosine, stir and mix, cool to 55-65℃, then add caffeine, stir and mix to obtain mixture A; S2. Dissolve glutathione and type 17 collagen peptide in water separately to obtain glutathione solution and type 17 collagen peptide solution. Add the two solutions together with β-sitosterol into mixture A and stir to obtain mixture B. S3. After cooling the mixture B to 40-50℃, add the co-delivery nanoliposomes of pyrrolidinyl diaminopyrimidine oxide and diaminopyrimidine oxide, pea sprout extract, ginsenosides, arborvitae leaf extract, co-delivery nanoliposomes of melatonin, and biotin. Stir and mix, and then cool to below 38℃ to obtain the final product.